JP2022509258A5 - - Google Patents

Info

Publication number
JP2022509258A5
JP2022509258A5 JP2021530885A JP2021530885A JP2022509258A5 JP 2022509258 A5 JP2022509258 A5 JP 2022509258A5 JP 2021530885 A JP2021530885 A JP 2021530885A JP 2021530885 A JP2021530885 A JP 2021530885A JP 2022509258 A5 JP2022509258 A5 JP 2022509258A5
Authority
JP
Japan
Application number
JP2021530885A
Other languages
Japanese (ja)
Other versions
JP2022509258A (ja
JP7535514B2 (ja
JPWO2020109864A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/001289 external-priority patent/WO2020109864A1/en
Publication of JP2022509258A publication Critical patent/JP2022509258A/ja
Publication of JPWO2020109864A5 publication Critical patent/JPWO2020109864A5/ja
Publication of JP2022509258A5 publication Critical patent/JP2022509258A5/ja
Priority to JP2024007364A priority Critical patent/JP2024028553A/ja
Application granted granted Critical
Publication of JP7535514B2 publication Critical patent/JP7535514B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021530885A 2018-11-30 2019-12-02 Dpep-1結合剤および使用の方法 Active JP7535514B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024007364A JP2024028553A (ja) 2018-11-30 2024-01-22 Dpep-1結合剤および使用の方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862773733P 2018-11-30 2018-11-30
US62/773,733 2018-11-30
PCT/IB2019/001289 WO2020109864A1 (en) 2018-11-30 2019-12-02 Dpep-1 binding agents and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024007364A Division JP2024028553A (ja) 2018-11-30 2024-01-22 Dpep-1結合剤および使用の方法

Publications (4)

Publication Number Publication Date
JP2022509258A JP2022509258A (ja) 2022-01-20
JPWO2020109864A5 JPWO2020109864A5 (https=) 2022-10-05
JP2022509258A5 true JP2022509258A5 (https=) 2022-10-05
JP7535514B2 JP7535514B2 (ja) 2024-08-16

Family

ID=70853301

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021530885A Active JP7535514B2 (ja) 2018-11-30 2019-12-02 Dpep-1結合剤および使用の方法
JP2024007364A Pending JP2024028553A (ja) 2018-11-30 2024-01-22 Dpep-1結合剤および使用の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024007364A Pending JP2024028553A (ja) 2018-11-30 2024-01-22 Dpep-1結合剤および使用の方法

Country Status (7)

Country Link
US (3) US11286278B2 (https=)
EP (1) EP3887390A4 (https=)
JP (2) JP7535514B2 (https=)
AU (1) AU2019386379B2 (https=)
CA (1) CA3121300A1 (https=)
IL (1) IL283231B1 (https=)
WO (1) WO2020109864A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7535514B2 (ja) * 2018-11-30 2024-08-16 アーチ バイオパートナーズ, インコーポレイテッド Dpep-1結合剤および使用の方法
EP4320167A4 (en) * 2021-04-08 2025-08-06 Nat Res Council Canada DPEP-1 BINDING AGENTS AND METHODS OF USE THEREOF
EP4574146A1 (en) 2023-12-18 2025-06-25 Telara Pharma S.L. Dhp-i inhibitors for use as neuroprotectants and in the treatment of neuroinflammatory diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223558B2 (en) * 2001-07-11 2007-05-29 Bristol-Myers Squibb Company Polynucleotides encoding three novel human cell surface proteins with leucine rich repeats and immunologobulin folds, BGS2, 3, and 4 and variants thereof
WO2007081751A2 (en) * 2006-01-05 2007-07-19 The Johns Hopkins University Compositions and methods for the treatment of cancer
EP2561359A1 (en) * 2010-04-20 2013-02-27 Addex Pharma SA Chimeric polypeptides useful in proximal and dynamic high-throughput screening methods
WO2012112420A1 (en) * 2011-02-14 2012-08-23 Allergan, Inc. Treatments using psma ligand endopeptidases
WO2015120536A1 (en) * 2014-02-13 2015-08-20 Arch Cancer Therapeutics, Inc. Peptides that block leukocyte recruitment and methods of use
ES3057215T3 (en) * 2015-08-11 2026-02-26 Arch Biopartners Inc Antagonist binding to dpep-1 for use in treating or preventing acute kidney injury or ischemia-reperfusion injury
EP3519443A4 (en) * 2016-09-30 2020-06-10 Baylor College of Medicine CHIMERIC ANTIGEN RECEPTOR THERAPY WITH REDUCED CYTOTOXICITY FOR VIRAL DISEASE
JP2019529499A (ja) * 2016-09-30 2019-10-17 ベイラー カレッジ オブ メディスンBaylor College Of Medicine 組織指向性発現を用いた抗体ベースの遺伝子治療
JP7535514B2 (ja) * 2018-11-30 2024-08-16 アーチ バイオパートナーズ, インコーポレイテッド Dpep-1結合剤および使用の方法

Similar Documents

Publication Publication Date Title
BR112021018450A2 (https=)
BR112021017892A2 (https=)
BR112021017939A2 (https=)
BR112021013944A2 (https=)
BR112021018452A2 (https=)
BR112021018102A2 (https=)
BR112021018168A2 (https=)
BR112021018093A2 (https=)
BR112021017083A2 (https=)
BR112021015080A2 (https=)
BR112021012348A2 (https=)
BR112021018250A2 (https=)
BR112021018584A2 (https=)
BR112021013128A2 (https=)
JP2022509258A5 (https=)
BR112021018484A2 (https=)
BR112021017949A2 (https=)
BR112021018084A2 (https=)
BR112021017983A2 (https=)
BR112021018193A2 (https=)
BR112021022805A2 (https=)
BR112021013854A2 (https=)
BR112021016784A2 (https=)
BR112021016205A2 (https=)
BR112021016099A2 (https=)